Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781243 | 1.00 | OPRK1 (0.44) | OPRK1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL7788436 | 0.82 | FOLH1 (0.56) | KMT2AMEN1ALDH1A1C3AR1 | |
| SCHEMBL7790273 | 0.81 | FOLH1 (0.45) | CTSGCMA1C3AR1 | |
| SCHEMBL7790264 | 0.81 | FOLH1 (0.45) | CTSGCMA1C3AR1 | |
| SCHEMBL7786368 | 0.79 | FOLH1 (0.49) | OPRK1ALDH1A1C3AR1 | |
| SCHEMBL7786354 | 0.79 | FOLH1 (0.49) | OPRK1ALDH1A1C3AR1 | |
| SCHEMBL7788448 | 0.78 | C3AR1 (0.44) | C3AR1 | |
| SCHEMBL7788437 | 0.78 | C3AR1 (0.44) | C3AR1 | |
| SCHEMBL4600052 | 0.76 | CHRM2 (0.52) | OPRK1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4600047 | 0.76 | CHRM2 (0.52) | OPRK1KMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | claimed |
| US-20010056185-A1 | C3A receptor ligands | LEE DENNIS (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | C3AR1, C5AR1, C5AR2 | OPRK1 1179/4885KMT2A 4425/4885MEN1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.